Le Lézard
Classified in: Health, Science and technology
Subject: Trade Show

Equillium Announces Two Abstracts Accepted for Presentation at the 63rd ASH Annual Meeting and Exposition


Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that two abstracts were accepted for presentation at the 63rd annual meeting of the American Society of Hematology to be held both in person and virtually, December 11 - 14, 2021.

Title: Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Combination with Corticosteroids, Is Well-Tolerated, with Rapid Pharmacodynamic and Clinical Response in Newly Diagnosed Acute Graft-Versus-Host Disease
First Author: Dr. John Koreth, associate professor of medicine, Dana Farber Cancer Institute, Harvard Medical School
Session Name: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II
Publication Number: 2891
Submission ID: 145721
Date: Sunday, December 12, 2021
Presentation Time: 6:00 PM - 8:00 PM
Location: Georgia World Congress Center, Hall B5

Title: Antigenic Modulation of CD6 By Itolizumab Is a New Mechanism for Effector T Cell Inhibition
First Author: Dalena Chu, Senior Research Associate, Equillium, Inc.,
Session Name: 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I
Publication Number: 995
Submission ID: 148805
Date: Saturday, December 11, 2021
Presentation Time: 5:30 PM - 7:30 PM
Location: Georgia World Congress Center, Hall B5

In addition to these presentations, abstracts will also be published online in the November supplemental issue of Blood.

About Graft-Versus-Host Disease (GVHD)

GVHD is a multisystem disorder that is a common complication of allogeneic hematopoietic stem cell transplants (allo-HSCT) caused by the transplanted immune system recognizing and attacking the recipient's body. Symptoms of GVHD include rash, itching, skin discoloration, nausea, vomiting, diarrhea, and jaundice, as well as eye dryness and irritation.

GVHD is the leading cause of non-relapse mortality in cancer patients receiving allo-HSCT, and its risk limits the number and type of patients receiving HSCT. GVHD results in high morbidity and mortality, with five-year survival of approximately 53% in patients who respond to steroid treatment and mortality as high as 95% in patients who do not respond to steroids. There are no approved treatments for first-line aGVHD. Published literature (MacMillan et al., 2015) describes background response rates to high-dose steroid administration in severe high-risk patients as 43% overall response and 27% complete response.

About Itolizumab

Itolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM signaling pathway to selectively downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited.

About Equillium

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

For more information, visit www.equilliumbio.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "could", "continue", "expect", "estimate", "may", "plan", "outlook", "future" and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to statements regarding the potential benefit of treating patients with aGVHD, uncontrolled asthma, or lupus/lupus nephritis with itolizumab, Equillium's plans and expected timing for developing itolizumab including the expected timing of initiating, completing and announcing further results from the EQUATE, EQUIP, and EQUALISE studies, the potential for any of Equillium's ongoing or planned clinical studies to show safety or efficacy, statements regarding the impact of new leadership team members, Equillium's anticipated timing of regulatory review and feedback, Equillium's cash runway, and Equillium's plans and expected timing for developing itolizumab and potential benefits of itolizumab. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties related to the abilities of the leadership team to perform as expected; Equillium's ability to execute its plans and strategies; risks related to performing clinical studies; the risk that interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; Equillium's plans and product development, including the initiation and completion of clinical studies and the reporting of data therefrom; whether the results from clinical studies will validate and support the safety and efficacy of itolizumab; changes in the competitive landscape; uncertainties related to Equillium's capital requirements; and having to use cash in ways or on timing other than expected and the impact of market volatility on cash reserves. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports with the SEC. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


These press releases may also interest you

at 09:10
A study published recently in Frontiers in Pediatrics shows B. infantis EVC001 is well-tolerated and improves human milk oligosaccharide utilization in preterm infants in the neonatal intensive care unit. Not all infants carry specialized gut...

at 09:07
According to the US Navy Veterans Lung Cancer Advocate, "We are appealing to the family of a Navy Veteran or person who has recently been diagnosed with lung cancer anywhere in the USA to please call attorney Erik Karst of the law firm of Karst von...

at 09:05
HeartVista, a pioneer in AI-powered MRI solutions, today announced that it has been selected by Stanford Health Care to deliver its One Click MRItm acquisition software on the hospital's existing Siemens Healthineers and GE Healthcare scanners. The...

at 09:05
Charles River Laboratories International, Inc. and Valo Health, LLC ("Valo"), the technology company using human-centric data and computation powered by artificial intelligence (AI) to transform the drug discovery and development process, today...

at 09:05
Dan Bessesen, MD, FTOS, a nutrition and obesity expert who has conducted research into nutrient metabolism and the regulation of body weight for the National Institutes of Health is the new president of The Obesity Society (TOS), the organization...

at 09:03
BrightPlan, a leader in Total Financial Wellness, today unveiled its strategy and first phase of new solutions for addressing four top challenges business and HR leaders continue to face in 2022: attracting and retaining talent, driving employee...



News published on 4 november 2021 at 09:15 and distributed by: